CH620202A5 - - Google Patents
Download PDFInfo
- Publication number
- CH620202A5 CH620202A5 CH576677A CH576677A CH620202A5 CH 620202 A5 CH620202 A5 CH 620202A5 CH 576677 A CH576677 A CH 576677A CH 576677 A CH576677 A CH 576677A CH 620202 A5 CH620202 A5 CH 620202A5
- Authority
- CH
- Switzerland
- Prior art keywords
- angiotensin
- lower alkyl
- methylpropanoyl
- hydrogen atom
- group
- Prior art date
Links
- -1 lower guanidinoalkyl Chemical group 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 16
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 11
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 11
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 10
- 102000015427 Angiotensins Human genes 0.000 claims description 9
- 108010064733 Angiotensins Proteins 0.000 claims description 9
- 206010020772 Hypertension Diseases 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 102000005862 Angiotensin II Human genes 0.000 claims description 8
- 101800000733 Angiotensin-2 Proteins 0.000 claims description 8
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 claims description 8
- 229950006323 angiotensin ii Drugs 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 101800000734 Angiotensin-1 Proteins 0.000 claims description 7
- 102400000344 Angiotensin-1 Human genes 0.000 claims description 7
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims description 7
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 230000003389 potentiating effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 101800004538 Bradykinin Proteins 0.000 claims description 2
- 102400000967 Bradykinin Human genes 0.000 claims description 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 238000005915 ammonolysis reaction Methods 0.000 claims description 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 claims description 2
- 230000001631 hypertensive effect Effects 0.000 claims description 2
- 125000005358 mercaptoalkyl group Chemical group 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 241000894007 species Species 0.000 claims description 2
- YTGJWQPHMWSCST-UHFFFAOYSA-N Tiopronin Chemical class CC(S)C(=O)NCC(O)=O YTGJWQPHMWSCST-UHFFFAOYSA-N 0.000 claims 5
- 102100028255 Renin Human genes 0.000 claims 4
- 108090000783 Renin Proteins 0.000 claims 4
- 108010058907 Tiopronin Proteins 0.000 claims 4
- 230000036772 blood pressure Effects 0.000 claims 4
- 102000004881 Angiotensinogen Human genes 0.000 claims 3
- 108090001067 Angiotensinogen Proteins 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 241000700159 Rattus Species 0.000 claims 2
- 201000003099 Renovascular Hypertension Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 1
- 102000004506 Blood Proteins Human genes 0.000 claims 1
- 108010017384 Blood Proteins Proteins 0.000 claims 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000000729 antidote Substances 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 229940093920 gynecological arsenic compound Drugs 0.000 claims 1
- 229910001385 heavy metal Inorganic materials 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000008714 homeostatic feedback mechanism Effects 0.000 claims 1
- 230000013632 homeostatic process Effects 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 201000005857 malignant hypertension Diseases 0.000 claims 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims 1
- 229910052753 mercury Inorganic materials 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000000144 pharmacologic effect Effects 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000003223 protective agent Substances 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940028870 thiola Drugs 0.000 claims 1
- 229960004402 tiopronin Drugs 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000047 product Substances 0.000 description 20
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000203 mixture Substances 0.000 description 14
- 239000004472 Lysine Substances 0.000 description 13
- 229960003646 lysine Drugs 0.000 description 13
- 229960004295 valine Drugs 0.000 description 13
- LUDPWTHDXSOXDX-UHFFFAOYSA-N s-(3-chloro-2-methyl-3-oxopropyl) ethanethioate Chemical compound ClC(=O)C(C)CSC(C)=O LUDPWTHDXSOXDX-UHFFFAOYSA-N 0.000 description 12
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 10
- 229930064664 L-arginine Natural products 0.000 description 10
- 235000014852 L-arginine Nutrition 0.000 description 10
- 229960005190 phenylalanine Drugs 0.000 description 10
- TUJAHMBTEMTOMQ-UHFFFAOYSA-N s-(3-chloro-3-oxopropyl) benzenecarbothioate Chemical compound ClC(=O)CCSC(=O)C1=CC=CC=C1 TUJAHMBTEMTOMQ-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 229960004799 tryptophan Drugs 0.000 description 9
- 239000000155 melt Substances 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 5
- 229960001230 asparagine Drugs 0.000 description 5
- 229960005261 aspartic acid Drugs 0.000 description 5
- 229960002743 glutamine Drugs 0.000 description 5
- 229960002885 histidine Drugs 0.000 description 5
- 229960001153 serine Drugs 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- VIVBGXXLVBMFBX-VIFPVBQESA-N (2s)-2-(3-benzoylsulfanylpropanoylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)CCSC(=O)C1=CC=CC=C1 VIVBGXXLVBMFBX-VIFPVBQESA-N 0.000 description 3
- AAXWBCKQYLBQKY-IRXDYDNUSA-N (2s)-2-[[(2s)-2-[(2-benzamidoacetyl)amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-4-methylpentanoic acid Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)C=1C=CC=CC=1)C1=CN=CN1 AAXWBCKQYLBQKY-IRXDYDNUSA-N 0.000 description 3
- CEDJTZWPFLMWMF-ZETCQYMHSA-N (2s)-4-methyl-2-(3-sulfanylpropanoylamino)pentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CCS CEDJTZWPFLMWMF-ZETCQYMHSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108010077895 Sarcosine Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000037020 contractile activity Effects 0.000 description 3
- 229960002433 cysteine Drugs 0.000 description 3
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 235000005772 leucine Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- SYIWWWZVQZBRJE-UHFFFAOYSA-N s-(2-benzyl-3-chloro-3-oxopropyl) ethanethioate Chemical compound CC(=O)SCC(C(Cl)=O)CC1=CC=CC=C1 SYIWWWZVQZBRJE-UHFFFAOYSA-N 0.000 description 3
- 229940043230 sarcosine Drugs 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- OFHKDLLHCJDJSR-BYPYZUCNSA-N (2r)-3-sulfanyl-2-(3-sulfanylpropanoylamino)propanoic acid Chemical compound OC(=O)[C@H](CS)NC(=O)CCS OFHKDLLHCJDJSR-BYPYZUCNSA-N 0.000 description 2
- JIAFOCJABIEPNM-BYPYZUCNSA-N (2s)-2-(3-sulfanylpropanoylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)CCS JIAFOCJABIEPNM-BYPYZUCNSA-N 0.000 description 2
- YAWGDXLGWYHPSX-MLWJPKLSSA-N (2s)-3-methyl-2-[(2-methyl-3-sulfanylpropanoyl)amino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)C(C)CS YAWGDXLGWYHPSX-MLWJPKLSSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 239000004201 L-cysteine Substances 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 229930195722 L-methionine Natural products 0.000 description 2
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 125000002707 L-tryptophyl group Chemical group [H]C1=C([H])C([H])=C2C(C([C@](N([H])[H])(C(=O)[*])[H])([H])[H])=C([H])N([H])C2=C1[H] 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- BWKJENFHBWHYFY-ZDUSSCGKSA-N (2s)-2-(3-benzoylsulfanylpropanoylamino)-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CCSC(=O)C1=CC=CC=C1 BWKJENFHBWHYFY-ZDUSSCGKSA-N 0.000 description 1
- ZJOWTIPPMQBTTA-LBPRGKRZSA-N (2s)-2-(benzylazaniumyl)-4-methylpentanoate Chemical group CC(C)C[C@@H](C(O)=O)NCC1=CC=CC=C1 ZJOWTIPPMQBTTA-LBPRGKRZSA-N 0.000 description 1
- XJODGRWDFZVTKW-LURJTMIESA-N (2s)-4-methyl-2-(methylamino)pentanoic acid Chemical group CN[C@H](C(O)=O)CC(C)C XJODGRWDFZVTKW-LURJTMIESA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- URUQJEBZRPLBCY-UHFFFAOYSA-N 2-[methyl-(4-oxo-4-phenylbutanethioyl)amino]acetic acid Chemical compound OC(=O)CN(C)C(=S)CCC(=O)C1=CC=CC=C1 URUQJEBZRPLBCY-UHFFFAOYSA-N 0.000 description 1
- RYNDYESLUKWOEE-UHFFFAOYSA-N 2-benzylprop-2-enoic acid Chemical compound OC(=O)C(=C)CC1=CC=CC=C1 RYNDYESLUKWOEE-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 1
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000002435 L-phenylalanyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003798 L-tyrosyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- SCIFESDRCALIIM-UHFFFAOYSA-N N-Me-Phenylalanine Natural products CNC(C(O)=O)CC1=CC=CC=C1 SCIFESDRCALIIM-UHFFFAOYSA-N 0.000 description 1
- 125000003556 N-methyl-L-phenylalanine group Chemical group 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- PHENPABYBHPABM-UHFFFAOYSA-N acetic acid;octane Chemical compound CC(O)=O.CCCCCCCC PHENPABYBHPABM-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical compound CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical class C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MRRPDAVMJQJUJA-UHFFFAOYSA-N s-(4-chloro-4-oxobutan-2-yl) ethanethioate Chemical compound ClC(=O)CC(C)SC(C)=O MRRPDAVMJQJUJA-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/14—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of sulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/684,606 US4053651A (en) | 1976-05-10 | 1976-05-10 | Compounds and method for alleviating angiotensin related hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH620202A5 true CH620202A5 (sv) | 1980-11-14 |
Family
ID=24748765
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH576677A CH620202A5 (sv) | 1976-05-10 | 1977-05-09 | |
| CH402580A CH621763A5 (sv) | 1976-05-10 | 1980-05-22 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH402580A CH621763A5 (sv) | 1976-05-10 | 1980-05-22 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US4053651A (sv) |
| JP (1) | JPS52136117A (sv) |
| AU (1) | AU513622B2 (sv) |
| BE (1) | BE854458A (sv) |
| CA (1) | CA1119177A (sv) |
| CH (2) | CH620202A5 (sv) |
| CS (1) | CS204001B2 (sv) |
| DD (1) | DD130477A5 (sv) |
| DE (1) | DE2717548A1 (sv) |
| DK (1) | DK203177A (sv) |
| FR (2) | FR2372624A1 (sv) |
| GB (1) | GB1577415A (sv) |
| HU (1) | HU177750B (sv) |
| IE (1) | IE44821B1 (sv) |
| NL (1) | NL7704712A (sv) |
| NO (1) | NO771623L (sv) |
| PL (2) | PL107991B1 (sv) |
| SE (1) | SE7705382L (sv) |
| SU (3) | SU818479A3 (sv) |
| YU (1) | YU116877A (sv) |
| ZA (1) | ZA772256B (sv) |
Families Citing this family (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS535112A (en) * | 1976-03-08 | 1978-01-18 | Santen Pharmaceutical Co Ltd | New cysteine derivatives |
| US4140797A (en) * | 1976-05-10 | 1979-02-20 | E. R. Squibb & Sons, Inc. | Method for alleviating angiotensin related hypertension |
| US4339600A (en) * | 1976-05-10 | 1982-07-13 | E. R. Squibb & Sons, Inc. | Compounds for alleviating angiotensin related hypertension |
| US4091024A (en) * | 1976-12-03 | 1978-05-23 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
| US4175199A (en) * | 1976-12-03 | 1979-11-20 | E. R. Squibb & Sons, Inc. | Substituted acyl derivatives of amino acids |
| US4206121A (en) * | 1976-12-03 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Substituted acyl derivatives of amino acids |
| US4178291A (en) * | 1976-12-03 | 1979-12-11 | E. R. Squibb & Sons, Inc. | Substituted acyl derivatives of amino acids |
| US4176235A (en) * | 1976-12-03 | 1979-11-27 | E. R. Squibb & Sons, Inc. | Substituted acyl derivatives of amino acids |
| US4116962A (en) * | 1976-12-03 | 1978-09-26 | E. R. Squibb & Sons, Inc. | Pyrrolidine and piperidine-2-carboxylic acid derivatives |
| US4113715A (en) * | 1977-01-17 | 1978-09-12 | E. R. Squibb & Sons, Inc. | Amino acid derivatives |
| US4611002A (en) * | 1977-07-14 | 1986-09-09 | E. R. Squibb And Sons, Inc. | Carboxymethyl esters of mercaptopropanoic acids as enkephalinase inhibitors |
| US4206137A (en) * | 1978-03-27 | 1980-06-03 | E. R. Squibb & Sons, Inc. | Thioalkanoylalkanoic acid compounds |
| US4927853A (en) * | 1978-04-24 | 1990-05-22 | Massachusetts Institute Of Technology | Composition for increasing blood pressure |
| US4690937A (en) * | 1979-08-14 | 1987-09-01 | University Of Miami | Anti-hypertensive agents |
| US4690939A (en) * | 1979-08-14 | 1987-09-01 | University Of Miami | Anti-hypertensive agents |
| US4698356A (en) * | 1979-08-14 | 1987-10-06 | University Of Miami | Anti-hypertensive agents |
| ZA794723B (en) * | 1978-09-11 | 1980-08-27 | Univ Miami | Anti-hypertensive agents |
| US4690938A (en) * | 1979-08-14 | 1987-09-01 | University Of Miami | Anti-hypertensive agents |
| US4695577A (en) * | 1979-08-14 | 1987-09-22 | University Of Miami | Anti-hypertensive agents |
| US4698355A (en) * | 1979-08-14 | 1987-10-06 | University Of Miami | Anti-hypertensive agents |
| US4690940A (en) * | 1979-08-14 | 1987-09-01 | University Of Miami | Anti-hypertensive agents |
| GR73585B (sv) * | 1978-09-11 | 1984-03-26 | Univ Miami | |
| JPS6011888B2 (ja) * | 1978-10-11 | 1985-03-28 | 参天製薬株式会社 | リウマチ疾患治療薬 |
| JPS6058908B2 (ja) * | 1978-10-11 | 1985-12-23 | 参天製薬株式会社 | システイン誘導体 |
| US4211786A (en) * | 1979-03-08 | 1980-07-08 | E. R. Squibb & Sons, Inc. | Mercaptoacyldihydropyrazole carboxylic acid derivatives |
| US4235885A (en) * | 1979-06-25 | 1980-11-25 | E. R. Squibb & Sons, Inc. | Inhibitors of mammalian collagenase |
| US4549992A (en) * | 1979-07-13 | 1985-10-29 | Usv Pharmaceutical Corp. | Antihypertensive amides |
| US4565825A (en) * | 1979-07-13 | 1986-01-21 | Usv Pharmaceutical Corp. | Antihypertensive N-benzimidazolyl- and N-imidazolyl-amino acid derivatives |
| US4256761A (en) * | 1979-07-13 | 1981-03-17 | Usv Pharmaceutical Corporation | Antihypertensive amides |
| DE2951353A1 (de) * | 1979-12-20 | 1981-07-02 | Basf Ag, 6700 Ludwigshafen | Kationische farbstoffe |
| PT70158A1 (en) * | 1980-03-03 | 1982-03-01 | Univ Miami | Process for preparing anti-hypertensive agents |
| US4734420A (en) * | 1980-03-05 | 1988-03-29 | University Of Miami | Anti-hypertensive agents |
| US4692458A (en) * | 1980-03-05 | 1987-09-08 | University Of Miami | Anti-hypertensive agents |
| US4690936A (en) * | 1980-03-05 | 1987-09-01 | University Of Miami | Anti-hypertensive agents |
| US4482725A (en) * | 1980-04-03 | 1984-11-13 | E. R. Squibb & Sons, Inc. | S-Acylation products of mercaptoacyl amino acids and carboxyl group containing diuretics |
| FR2480747A1 (fr) * | 1980-04-17 | 1981-10-23 | Roques Bernard | Derives d'acides amines et leur application therapeutique |
| ZA811340B (en) * | 1980-06-09 | 1982-03-31 | Morton Norwich Products Inc | N-(cycloalkyl)amino acid compounds |
| AU543804B2 (en) * | 1980-10-31 | 1985-05-02 | Takeda Chemical Industries Ltd. | Amides having bicyclic substituents on nitrogen |
| US4521607A (en) * | 1981-02-27 | 1985-06-04 | Takeda Chemical Industries, Ltd. | Chromanyl glycines |
| JPS57142962A (en) * | 1981-02-28 | 1982-09-03 | Santen Pharmaceut Co Ltd | Cyclodextrin clathrate compound of sulfur-containing compound |
| US4329495A (en) * | 1981-05-18 | 1982-05-11 | Pfizer Inc. | Enkephalinase enzyme inhibiting compounds |
| US4432972A (en) * | 1981-08-03 | 1984-02-21 | E. R. Squibb & Sons, Inc. | Phosphonamidate compounds |
| US4432971A (en) * | 1981-08-03 | 1984-02-21 | E. R. Squibb & Sons, Inc. | Phosphonamidate compounds |
| US4474795A (en) * | 1981-10-09 | 1984-10-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4474799A (en) * | 1981-10-09 | 1984-10-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4401677A (en) * | 1981-10-09 | 1983-08-30 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4396772A (en) * | 1981-11-23 | 1983-08-02 | F. R. Squibb & Sons, Inc. | Phosphinylalkanoyl amino acids |
| IT1140394B (it) * | 1981-12-23 | 1986-09-24 | Maggioni Farma | Dipeptidi contenenti un residuo di metionina ad attivita' epatoprotettrice |
| US4555506A (en) * | 1981-12-24 | 1985-11-26 | E. R. Squibb & Sons, Inc. | Phosphorus containing compounds and use as hypotensives |
| JPS58140065A (ja) * | 1982-02-10 | 1983-08-19 | Meito Sangyo Kk | メルカプトベンジル脂肪酸誘導体類及びその製法 |
| US4452791A (en) * | 1982-03-15 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
| US4560680A (en) * | 1982-03-15 | 1985-12-24 | E. R. Squibb & Sons, Inc. | Aminoalkyl and related substituted phosphinic acid angiotensin converting enzyme inhibitors |
| US4616005A (en) * | 1982-06-23 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US4703043A (en) * | 1982-06-23 | 1987-10-27 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensive |
| US4452790A (en) * | 1982-06-23 | 1984-06-05 | E. R. Squibb & Sons, Inc. | Phosphonyl hydroxyacyl amino acid derivatives as antihypertensives |
| US4736066A (en) * | 1982-07-19 | 1988-04-05 | E. R. Squibb & Sons, Inc. | Intermediate for substituted peptide compounds |
| US4470973A (en) * | 1982-07-19 | 1984-09-11 | E. R. Squibb & Sons, Inc. | Substituted peptide compounds |
| IL69228A0 (en) * | 1982-07-21 | 1983-11-30 | Usv Pharma Corp | Compounds having diuretic activity and angiotensin converting inhibitory activity,methods of the preparation thereof and pharmaceutical compositions containing the same |
| US4661515A (en) * | 1982-07-21 | 1987-04-28 | Usv Pharmaceutical Corporation | Compounds having angiotensin converting enzyme inhibitory activity and diuretic activity |
| US4623729A (en) | 1982-07-22 | 1986-11-18 | E. R. Squibb & Sons, Inc. | Acylalkylaminocarbonyl substituted amino and imino acid compounds |
| US4742067A (en) * | 1982-07-22 | 1988-05-03 | E. R. Squibb & Sons, Inc. | Acylalkylaminocarbonyl substituted amino and imino acid compounds |
| US4621092A (en) * | 1982-07-22 | 1986-11-04 | E. R. Squibb & Sons, Inc. | Substituted proline compounds, composition and method of use |
| US4524212A (en) * | 1982-09-27 | 1985-06-18 | E. R. Squibb & Sons, Inc. | Acyloxyketone substituted imino and amino acids |
| FR2540495B1 (fr) * | 1983-02-07 | 1986-02-14 | Roussel Uclaf | Nouveaux derives de o-mercaptopropanamide et de ses homologues, leur procede de preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus |
| US4798904A (en) * | 1983-10-03 | 1989-01-17 | E. R. Squibb & Sons, Inc. | Certain [(lower alkanoyl-thio)methyl-1-oxo-3-phenyl propyl amino]benzene lower alkanoic acid or ester derivatives which inhibit enkephalinase |
| US4774256A (en) * | 1983-10-03 | 1988-09-27 | E. R. Squibb & Sons, Inc. | Use of enkephalinase inhibitors as analgesic agents |
| US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US4595700A (en) * | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
| EP0254032A3 (en) * | 1986-06-20 | 1990-09-05 | Schering Corporation | Neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| US4929641B1 (en) * | 1988-05-11 | 1994-08-30 | Schering Corp | Mercapto-acylamino acid antihypertensives |
| US4801609B1 (en) * | 1987-03-27 | 1993-11-09 | Mercapto-acylamino acid antihypertensives | |
| US5262436A (en) * | 1987-03-27 | 1993-11-16 | Schering Corporation | Acylamino acid antihypertensives in the treatment of congestive heart failure |
| CA1337400C (en) * | 1987-06-08 | 1995-10-24 | Norma G. Delaney | Inhibitors of neutral endopeptidase |
| US5179125A (en) * | 1987-12-03 | 1993-01-12 | Dainippon Pharmaceutical Co., Ltd. | N-substituted mercaptopropanamide derivatives |
| US5210266A (en) * | 1987-12-03 | 1993-05-11 | Dainippon Pharmaceutical Co., Ltd. | N-substituted mercaptopropanamide derivatives |
| EP0318859A3 (en) * | 1987-12-03 | 1990-08-16 | Dainippon Pharmaceutical Co., Ltd. | N-substituted mercaptopropanamide derivatives |
| US5292926A (en) * | 1988-01-25 | 1994-03-08 | Santen Pharmaceutical Co., Ltd. | Cysteine derivatives |
| US5002964A (en) * | 1988-06-15 | 1991-03-26 | Brigham & Women's Hospital | S-nitrosocaptopril compounds and the use thereof |
| US5356890A (en) * | 1988-06-15 | 1994-10-18 | Brigham And Women's Hospital | S-nitroso derivatives of ace inhibitors and the use thereof |
| US5025001A (en) * | 1988-06-15 | 1991-06-18 | Brigham And Women's Hospital | S-nitroso derivatives of ACE inhibitors and the use thereof |
| US5187183A (en) * | 1988-06-15 | 1993-02-16 | Brigham & Women's Hospital | S-nitroso derivatives of ACE inhibitors and the use thereof |
| US4879309A (en) * | 1988-09-27 | 1989-11-07 | Schering Corporation | Mercapto-acylamino acids as antihypertensives |
| ZA902661B (en) * | 1989-04-10 | 1991-01-30 | Schering Corp | Mercapto-acyl amino acids |
| CA2021409A1 (en) * | 1989-08-21 | 1991-02-22 | Donald S. Karanewsky | Phosphonate substituted amino or imino acids useful as antihypertensives |
| WO1991009840A1 (en) * | 1989-12-22 | 1991-07-11 | Schering Corporation | Mercaptocycloacyl aminoacid endopeptidase inhibitors |
| IL98149A0 (en) * | 1990-05-17 | 1992-06-21 | Schering Corp | Disulfide derivatives of mercapto-acylamino acids |
| FR2679564A1 (fr) * | 1991-07-23 | 1993-01-29 | Inst Nat Sante Rech Med | Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent. |
| US5504080A (en) * | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
| US5424447A (en) * | 1993-07-07 | 1995-06-13 | The Medical College Of Wisconsin Research Foundation, Inc. | Heme binding compounds and use thereof |
| FR2712286B1 (fr) * | 1993-11-12 | 1995-12-22 | Oreal | Nouveaux N-mercaptoalkyl alcanediamines et leur utilisation. |
| DE4430023A1 (de) * | 1994-08-24 | 1996-02-29 | Boehringer Mannheim Gmbh | Elektrochemischer Sensor |
| IT1273455B (it) * | 1995-01-27 | 1997-07-08 | Zambon Spa | Derivati tiolici ad attivita' inibitrice delle metallopeptidasi |
| US5670545A (en) * | 1996-02-09 | 1997-09-23 | Board Of Regents Of The University Of Colorado | Method for the treatment of ischemic disease and reperfusion injury and the prevention of the adverse effects of reactive oxygen species |
| FR2745571B1 (fr) * | 1996-03-04 | 1998-06-19 | Inst Nat Sante Rech Med | Nouveaux derives soufres comportant une liaison amide, leur procede de preparation, leur application a titre de medicaments, et les compositions pharmaceutiques les renfermant |
| GB0221169D0 (en) | 2002-09-12 | 2002-10-23 | Univ Bath | Crystal |
| GB0600406D0 (en) | 2006-01-10 | 2006-02-15 | Univ Bath | Crystal |
| US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
| US9259535B2 (en) | 2006-06-22 | 2016-02-16 | Excelsior Medical Corporation | Antiseptic cap equipped syringe |
| US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
| US9849276B2 (en) | 2011-07-12 | 2017-12-26 | Pursuit Vascular, Inc. | Method of delivering antimicrobial to a catheter |
| WO2011113774A1 (en) * | 2010-03-17 | 2011-09-22 | Akzo Nobel Chemicals International B.V. | Process for depolymerizing polysulfides and the preparation of bis-mercapto-diethers |
| AU2015252808B2 (en) | 2014-05-02 | 2019-02-21 | Excelsior Medical Corporation | Strip package for antiseptic cap |
| PL224139B1 (pl) | 2014-08-01 | 2016-11-30 | Ekobenz Spółka Z Ograniczoną Odpowiedzialnością | Mieszanka paliwowa szczególnie do silników z zapłonem iskrowym |
| EP3294404A4 (en) | 2015-05-08 | 2018-11-14 | ICU Medical, Inc. | Medical connectors configured to receive emitters of therapeutic agents |
| DK3525865T3 (da) | 2016-10-14 | 2022-10-24 | Icu Medical Inc | Desinficerende hætter til medicinsk konnektorer |
| WO2018204206A2 (en) | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
| US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
| US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
| US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
| US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
| US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
| WO2020106985A1 (en) | 2018-11-21 | 2020-05-28 | Pursuit Vascular, Inc. | Antimicrobial device comprising a cap with ring and insert |
| WO2022125474A1 (en) | 2020-12-07 | 2022-06-16 | Icu Medical, Inc. | Peritoneal dialysis caps, systems and methods |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH451186A (de) * | 1961-11-02 | 1968-05-15 | Santen Phamarceutical Co Ltd | Verfahren zur Herstellung von N-Mercaptopropionylglycin und dessen Derivaten |
| CA1009252A (en) | 1972-10-03 | 1977-04-26 | Santen Pharmaceutical Co. | N-(mercaptoacyl) aminoacids |
| US3857951A (en) * | 1973-09-14 | 1974-12-31 | Cassenne Lab Sa | Use of 2-mercaptopropionylglycine and its alkali metal salts in treating respiratory diseases |
| AU509899B2 (en) | 1976-02-13 | 1980-05-29 | E.R. Squibb & Sons, Inc. | Proline derivatives and related compounds |
-
1976
- 1976-05-10 US US05/684,606 patent/US4053651A/en not_active Expired - Lifetime
-
1977
- 1977-03-03 US US05/773,865 patent/US4112119A/en not_active Expired - Lifetime
- 1977-04-07 AU AU24106/77A patent/AU513622B2/en not_active Expired
- 1977-04-13 ZA ZA00772256A patent/ZA772256B/xx unknown
- 1977-04-13 CA CA000276034A patent/CA1119177A/en not_active Expired
- 1977-04-14 GB GB15559/77A patent/GB1577415A/en not_active Expired
- 1977-04-14 IE IE783/77A patent/IE44821B1/en not_active IP Right Cessation
- 1977-04-20 DE DE19772717548 patent/DE2717548A1/de active Granted
- 1977-04-21 CS CS772657A patent/CS204001B2/cs unknown
- 1977-04-29 NL NL7704712A patent/NL7704712A/xx not_active Application Discontinuation
- 1977-05-03 DD DD7700198728A patent/DD130477A5/xx unknown
- 1977-05-04 FR FR7713595A patent/FR2372624A1/fr active Granted
- 1977-05-07 PL PL1977197963A patent/PL107991B1/pl unknown
- 1977-05-07 PL PL1977205447A patent/PL106032B1/pl unknown
- 1977-05-09 SE SE7705382A patent/SE7705382L/sv not_active Application Discontinuation
- 1977-05-09 DK DK203177A patent/DK203177A/da unknown
- 1977-05-09 YU YU01168/77A patent/YU116877A/xx unknown
- 1977-05-09 NO NO771623A patent/NO771623L/no unknown
- 1977-05-09 HU HU77SU947A patent/HU177750B/hu unknown
- 1977-05-09 CH CH576677A patent/CH620202A5/fr not_active IP Right Cessation
- 1977-05-10 JP JP5420177A patent/JPS52136117A/ja active Granted
- 1977-05-10 SU SU772478851A patent/SU818479A3/ru active
- 1977-05-10 BE BE177439A patent/BE854458A/xx not_active IP Right Cessation
-
1978
- 1978-01-18 FR FR7801417A patent/FR2367741A1/fr active Granted
- 1978-07-05 SU SU782632600A patent/SU697049A3/ru active
- 1978-07-05 SU SU782632596A patent/SU955857A3/ru active
-
1980
- 1980-05-22 CH CH402580A patent/CH621763A5/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE2717548C2 (sv) | 1990-05-03 |
| CS204001B2 (en) | 1981-03-31 |
| SE7705382L (sv) | 1977-11-11 |
| IE44821B1 (en) | 1982-04-07 |
| CA1119177A (en) | 1982-03-02 |
| DK203177A (da) | 1977-11-11 |
| PL106032B1 (pl) | 1979-11-30 |
| CH621763A5 (sv) | 1981-02-27 |
| FR2372624A1 (fr) | 1978-06-30 |
| SU697049A3 (ru) | 1979-11-05 |
| SU818479A3 (ru) | 1981-03-30 |
| FR2367741B1 (sv) | 1982-10-29 |
| US4112119A (en) | 1978-09-05 |
| FR2367741A1 (fr) | 1978-05-12 |
| HU177750B (en) | 1981-12-28 |
| DE2717548A1 (de) | 1977-12-01 |
| SU955857A3 (ru) | 1982-08-30 |
| IE44821L (en) | 1977-11-10 |
| PL107991B1 (pl) | 1980-03-31 |
| FR2372624B1 (sv) | 1980-05-09 |
| JPS52136117A (en) | 1977-11-14 |
| ZA772256B (en) | 1978-03-29 |
| AU2410677A (en) | 1978-10-12 |
| YU116877A (en) | 1982-08-31 |
| NL7704712A (nl) | 1977-11-14 |
| GB1577415A (en) | 1980-10-22 |
| JPS6120544B2 (sv) | 1986-05-22 |
| NO771623L (no) | 1977-11-11 |
| PL197963A1 (pl) | 1978-03-28 |
| BE854458A (fr) | 1977-11-10 |
| AU513622B2 (en) | 1980-12-11 |
| US4053651A (en) | 1977-10-11 |
| DD130477A5 (de) | 1978-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH620202A5 (sv) | ||
| US4339600A (en) | Compounds for alleviating angiotensin related hypertension | |
| US4199512A (en) | Compounds for alleviating hypertension | |
| EP0308341B1 (fr) | Procédé de synthèse industrielle du périndopril et de ses principaux intermédiaires de synthèse | |
| EP0687251B1 (fr) | Derives de 1,3-dihydroindol-2-one substitues en 3 par un groupe azote comme agonistes et/ou antagonistes de la vasopressine et/ou de l'ocytocine | |
| EP0082088B1 (fr) | Nouveaux dérivés d'aminoacides, et leur application thérapeutique | |
| FR2679564A1 (fr) | Nouveaux acylmercaptoalcanoldipeptides, leur preparation et les compositions qui les contiennent. | |
| EP0462884A1 (fr) | Dérivés de TRH, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| JPS6388166A (ja) | ジアミン類の選択的アミジン化 | |
| FR2511036A1 (fr) | Procede de preparation de derives d'insuline et produits obtenus | |
| CA2405466C (fr) | Nouveau procede de synthese des esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril | |
| CA2404700C (fr) | Nouveau procede de synthese de esters de la n-[(s)-1-carboxybutyl]-(s)-alanine et application a la synthese du perindopril | |
| US4140797A (en) | Method for alleviating angiotensin related hypertension | |
| US4173704A (en) | Dithio aminoacid derivatives | |
| CH665645A5 (fr) | Derives de dipeptides et leur procede de preparation. | |
| EP0723974B1 (fr) | Dérivés de mercaptoalcanoyldipeptides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
| FR2575163A1 (fr) | Tri- et tetrapeptides reduits inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant | |
| FR2689764A1 (fr) | Utilisation de dérivés de peptides pour la fabrication de médicaments inhibiteurs des endopeptidases 24.15 et 24.16. | |
| US4192881A (en) | Carboxyalkylacyl substituted imidazolylamino acids | |
| CS204002B2 (cs) | Způsob přípravy merkaptoacylaminokyselin | |
| EP0680972A1 (fr) | Peptides dérivés de trifluorométhylcétones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |